Email updates

Keep up to date with the latest news and content from Genome Biology and BioMed Central.

Research news

Agrin therapy

Jonathan B Weitzman

Author Affiliations

Genome Biology 2001, 2:spotlight-20010920-01  doi:10.1186/gb-spotlight-20010920-01


The electronic version of this article is the complete one and can be found online at:


Published:20 September 2001

© 2001 BioMed Central Ltd

Research news

Congenital muscular dystrophy is a severe muscle-wasting disease that is often caused by mutations in LAMA2, the gene encoding the laminin α2 chain expressed by muscle fibres. In the September 20 Nature, Joachim Moll and colleagues at the University of Basel, Switzerland, report that an agrin minigene can rescue dystrophic symptoms in a mouse model of the disease (Nature 2001, 413:302-307). The researchers reasoned that agrin, which binds to laminin and to α-drystroglycan, might be able to functionally rescue the weakened muscle caused by LAMA2 mutations. They designed a truncated mini-agrin construct driven by the muscle creatine kinase promoter. They crossed mice expressing the mini-agrin transgene (mag-tg) with animals lacking a functional lama2 gene. The agrin transgene improved the general health, lifespan and locomotory activity of the mutant mice. The agrin transgene also rescued the muscle degeneration phenotype. This study demonstrates the potential for gene therapy using non-homologous proteins that functionally compensate for gene mutation.

References

  1. [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=156225] webcite

    LAMA2

  2. [http://www.nature.com] webcite

    Nature

  3. [http://www.unibas.ch] webcite

    University of Basel

  4. Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models.

    PubMed Abstract | Publisher Full Text OpenURL